MX2023005873A - Tratamiento del cancer. - Google Patents
Tratamiento del cancer.Info
- Publication number
- MX2023005873A MX2023005873A MX2023005873A MX2023005873A MX2023005873A MX 2023005873 A MX2023005873 A MX 2023005873A MX 2023005873 A MX2023005873 A MX 2023005873A MX 2023005873 A MX2023005873 A MX 2023005873A MX 2023005873 A MX2023005873 A MX 2023005873A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cancer
- nectin
- chemotherapeutic agents
- binding
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 102100035486 Nectin-4 Human genes 0.000 abstract 1
- 101710043865 Nectin-4 Proteins 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La invención se refiere a proteínas de unión a antígeno capaces de unirse a polipéptidos de Nectina-4 conjugados con agentes quimioterapéuticos, para su uso en el aumento de la sensibilidad de los tumores a los agentes quimioterapéuticos y para su uso en el tratamiento de cánceres que se caracterizan por células tumorales que expresan Nectina-4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063118198P | 2020-11-25 | 2020-11-25 | |
US202163229589P | 2021-08-05 | 2021-08-05 | |
PCT/EP2021/082872 WO2022112356A1 (en) | 2020-11-25 | 2021-11-24 | Treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023005873A true MX2023005873A (es) | 2023-06-05 |
Family
ID=78819544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005873A MX2023005873A (es) | 2020-11-25 | 2021-11-24 | Tratamiento del cancer. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4251207A1 (es) |
JP (1) | JP2024501121A (es) |
KR (1) | KR20230112656A (es) |
AU (1) | AU2021387795A1 (es) |
CA (1) | CA3196198A1 (es) |
IL (1) | IL302818A (es) |
MX (1) | MX2023005873A (es) |
WO (1) | WO2022112356A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4285935A1 (en) * | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
WO2023237050A1 (en) * | 2022-06-09 | 2023-12-14 | Beigene, Ltd. | Antibody drug conjugates |
EP4309676A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4344707A1 (en) * | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
WO2024078449A1 (en) * | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
EP1080732A4 (en) | 1998-05-22 | 2004-08-25 | Daiichi Seiyaku Co | DRUG COMPOSITION |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
KR101048279B1 (ko) | 2002-05-30 | 2011-07-13 | 더 스크립스 리서치 인스티튜트 | 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션 |
ATE322499T1 (de) | 2002-11-11 | 2006-04-15 | Verfahren zur herstellung von 2-keto-l-gulonsäure-c-4 c-10 /sb -alkylestern | |
JP2006507322A (ja) | 2002-11-14 | 2006-03-02 | シンタルガ・ビーブイ | 多重自己脱離放出スペーサーとして構築されたプロドラッグ |
KR101192496B1 (ko) | 2003-11-06 | 2012-10-18 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
JP5064037B2 (ja) | 2004-02-23 | 2012-10-31 | ジェネンテック, インコーポレイテッド | 複素環式自壊的リンカーおよび結合体 |
PT2270010E (pt) | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
PT1812031E (pt) | 2004-11-01 | 2015-10-01 | Univ California | Composições e métodos para modificação de biomoléculas |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
EP2222341B1 (en) | 2007-11-21 | 2015-02-25 | University Of Georgia Research Foundation, Inc. | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
JP2012511305A (ja) * | 2008-12-12 | 2012-05-24 | オンコセラピー・サイエンス株式会社 | 癌の治療および診断の標的遺伝子としてのネクチン−4 |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
EP2552453A2 (en) | 2010-03-30 | 2013-02-06 | Clavis Pharma ASA | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
ES2680624T3 (es) | 2010-09-29 | 2018-09-10 | Agensys, Inc. | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
KR20190089048A (ko) | 2011-02-15 | 2019-07-29 | 이뮤노젠 아이엔씨 | 컨쥬게이트의 제조방법 |
CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6747971B2 (ja) | 2013-10-15 | 2020-08-26 | シアトル ジェネティックス, インコーポレイテッド | 改善されたリガンド−薬物コンジュゲート薬物動態のためのpeg化薬物−リンカー |
JP6733993B2 (ja) | 2014-10-03 | 2020-08-05 | シンアフィックス ビー.ブイ. | スルファミドリンカー、スルファミドリンカーのコンジュゲート、及び調製の方法 |
KR20230158134A (ko) | 2014-10-14 | 2023-11-17 | 폴리테릭스 리미티드 | Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법 |
CN110392697A (zh) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
BR112019025513A2 (pt) * | 2017-06-05 | 2020-06-23 | Agensys, Inc. | Proteínas de ligação à nectina-4 e métodos de uso das mesmas |
US20200345863A1 (en) | 2017-10-23 | 2020-11-05 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
WO2020188061A1 (en) | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
KR20220079614A (ko) * | 2019-10-07 | 2022-06-13 | 위니베르시떼 덱스-마르세이유 | 넥틴-4에 대한 특이성을 갖는 항체 및 이의 용도 |
EP4065173A4 (en) * | 2019-11-25 | 2024-03-27 | Agensys Inc | TREATMENT OF CANCERS WITH ANTIBODY-DRUG CONJUGATES (ADC) BINDING TO 191P4D12 PROTEINS |
CN114845740A (zh) * | 2020-01-31 | 2022-08-02 | 先天制药公司 | 癌症的治疗 |
CN113527486A (zh) * | 2020-04-21 | 2021-10-22 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
MX2022016192A (es) * | 2020-06-18 | 2023-04-27 | Bioatla Inc | Anticuerpos anti-nectina-4 condicionalmente activos. |
-
2021
- 2021-11-24 JP JP2023531534A patent/JP2024501121A/ja active Pending
- 2021-11-24 KR KR1020237019929A patent/KR20230112656A/ko unknown
- 2021-11-24 WO PCT/EP2021/082872 patent/WO2022112356A1/en active Application Filing
- 2021-11-24 MX MX2023005873A patent/MX2023005873A/es unknown
- 2021-11-24 IL IL302818A patent/IL302818A/en unknown
- 2021-11-24 AU AU2021387795A patent/AU2021387795A1/en active Pending
- 2021-11-24 EP EP21816063.8A patent/EP4251207A1/en active Pending
- 2021-11-24 CA CA3196198A patent/CA3196198A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3196198A1 (en) | 2022-06-02 |
KR20230112656A (ko) | 2023-07-27 |
EP4251207A1 (en) | 2023-10-04 |
AU2021387795A1 (en) | 2023-06-01 |
IL302818A (en) | 2023-07-01 |
WO2022112356A1 (en) | 2022-06-02 |
JP2024501121A (ja) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005873A (es) | Tratamiento del cancer. | |
PH12019500550A1 (en) | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates | |
AU2019416117B2 (en) | CSF1R inhibitors for use in treating cancer | |
CY1119324T1 (el) | Αντισωματα εναντιον csf-1r | |
MY160628A (en) | Therapeutic DLL4 Binding Proteins | |
CY1120288T1 (el) | Συζευγματα αντισωματος-φαρμακου που περιεχουν duocarmycin για χρηση στη θεραπεια του καρκινου της ουροδοχου κυστης | |
EA201390328A1 (ru) | Новые антигенсвязывающие белки | |
AR077998A1 (es) | Proteinas terapeuticas de union a dll4 | |
WO2016059602A3 (en) | Combination therapy with anti-her3 antibodies to treat cancer | |
UA106492C2 (uk) | Імунокон'югати анти-мезотеліну, їх застосування та одержання | |
MX2013011363A (es) | Anticuerpos para peptidos citosolicos. | |
MX2020012091A (es) | Composiciones anti-cd24 y usos de las mismas. | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
RU2017138468A (ru) | Антитела против человеческого her3, имеющие низкое содержание фукозы, и области их применения | |
MX2020011487A (es) | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. | |
EP3693022A3 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
MX2023002940A (es) | Moleculas de union a b7-h4 terapeuticas. | |
EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
MX2022006289A (es) | Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12. | |
MX2023007644A (es) | Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2. | |
MX2021009514A (es) | Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
MX2022001731A (es) | Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12. |